PARP1 and neoplasm: Given this functional interplay, it has been postulated that FA dysfunctional tumours, or targeting of the FA pathway, may render them sensitive to PARP1 inhibitors [170, 171, 172], as well as a multitude of other drug targeting strategies within the FA and related DDR pathways [170].